164 related articles for article (PubMed ID: 36691310)
1. Introducing an important therapy for obesity to primary care: once-weekly subcutaneous semaglutide 2.4 mg.
Kyrillos JV; O'Neil PM; Wharton S
Postgrad Med; 2022 Jan; 134(sup1):1-4. PubMed ID: 36691310
[No Abstract] [Full Text] [Related]
2. Wegovy (semaglutide): a new weight loss drug for chronic weight management.
Singh G; Krauthamer M; Bjalme-Evans M
J Investig Med; 2022 Jan; 70(1):5-13. PubMed ID: 34706925
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological profile of once-weekly injectable semaglutide for chronic weight management.
Lau DCW; Batterham RL; le Roux CW
Expert Rev Clin Pharmacol; 2022 Mar; 15(3):251-267. PubMed ID: 35466848
[TBL] [Abstract][Full Text] [Related]
4. Integrating semaglutide into obesity management - a primary care perspective.
Kyrillos JV; Skolnik NS; Mukhopadhyay B; Pennings N
Postgrad Med; 2022 Jan; 134(sup1):37-49. PubMed ID: 36691306
[TBL] [Abstract][Full Text] [Related]
5. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.
Davies M; Færch L; Jeppesen OK; Pakseresht A; Pedersen SD; Perreault L; Rosenstock J; Shimomura I; Viljoen A; Wadden TA; Lingvay I;
Lancet; 2021 Mar; 397(10278):971-984. PubMed ID: 33667417
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials.
Aroda VR; Ahmann A; Cariou B; Chow F; Davies MJ; Jódar E; Mehta R; Woo V; Lingvay I
Diabetes Metab; 2019 Oct; 45(5):409-418. PubMed ID: 30615985
[TBL] [Abstract][Full Text] [Related]
7. Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis.
Hansen BB; Nuhoho S; Ali SN; Dang-Tan T; Valentine WJ; Malkin SJP; Hunt B
J Med Econ; 2020 Jun; 23(6):650-658. PubMed ID: 31990244
[No Abstract] [Full Text] [Related]
8. Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10).
Capehorn MS; Catarig AM; Furberg JK; Janez A; Price HC; Tadayon S; Vergès B; Marre M
Diabetes Metab; 2020 Apr; 46(2):100-109. PubMed ID: 31539622
[TBL] [Abstract][Full Text] [Related]
9. [Semaglutide, once weekly GLP-1 receptor agonist (Ozempic®)].
Scheen AJ
Rev Med Liege; 2019 Sep; 74(9):488-494. PubMed ID: 31486321
[TBL] [Abstract][Full Text] [Related]
10. A Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian Subjects.
Ikushima I; Jensen L; Flint A; Nishida T; Zacho J; Irie S
Adv Ther; 2018 Apr; 35(4):531-544. PubMed ID: 29536338
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of semaglutide for weight management: evidence from the STEP program.
Amaro A; Sugimoto D; Wharton S
Postgrad Med; 2022 Jan; 134(sup1):5-17. PubMed ID: 36691309
[TBL] [Abstract][Full Text] [Related]
12. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
Rubino DM; Greenway FL; Khalid U; O'Neil PM; Rosenstock J; Sørrig R; Wadden TA; Wizert A; Garvey WT;
JAMA; 2022 Jan; 327(2):138-150. PubMed ID: 35015037
[TBL] [Abstract][Full Text] [Related]
13. Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozin.
Gorgojo-Martínez JJ; Malkin SJP; Martín V; Hallén N; Hunt B
J Med Econ; 2020 Feb; 23(2):193-203. PubMed ID: 31613199
[No Abstract] [Full Text] [Related]
14. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5.
Kushner RF; Calanna S; Davies M; Dicker D; Garvey WT; Goldman B; Lingvay I; Thomsen M; Wadden TA; Wharton S; Wilding JPH; Rubino D
Obesity (Silver Spring); 2020 Jun; 28(6):1050-1061. PubMed ID: 32441473
[TBL] [Abstract][Full Text] [Related]
15. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.
Rubino D; Abrahamsson N; Davies M; Hesse D; Greenway FL; Jensen C; Lingvay I; Mosenzon O; Rosenstock J; Rubio MA; Rudofsky G; Tadayon S; Wadden TA; Dicker D;
JAMA; 2021 Apr; 325(14):1414-1425. PubMed ID: 33755728
[TBL] [Abstract][Full Text] [Related]
16. Semaglutide: First Global Approval.
Dhillon S
Drugs; 2018 Feb; 78(2):275-284. PubMed ID: 29363040
[TBL] [Abstract][Full Text] [Related]
17. The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia.
Malkin SJP; Russel-Szymczyk M; Psota M; Hlavinkova L; Hunt B
Adv Ther; 2019 Aug; 36(8):2034-2051. PubMed ID: 31168765
[TBL] [Abstract][Full Text] [Related]
18. Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK.
Johansen P; Chubb B; Hunt B; Malkin SJP; Sandberg A; Capehorn M
Adv Ther; 2020 May; 37(5):2427-2441. PubMed ID: 32306244
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: a meta-analysis.
Zhong P; Zeng H; Huang M; Fu W; Chen Z
Endocrine; 2022 Mar; 75(3):718-724. PubMed ID: 34981419
[TBL] [Abstract][Full Text] [Related]
20. Once-Weekly Semaglutide in Adolescents with Obesity.
Malozowski S
N Engl J Med; 2023 Mar; 388(12):1145-1146. PubMed ID: 36947475
[No Abstract] [Full Text] [Related]
[Next] [New Search]
